Literature DB >> 20460922

The effect of lifestyle changes in non-alcoholic fatty liver disease.

Elena Centis1, Rebecca Marzocchi, Silvia Di Domizio, Maria Francesca Ciaravella, Giulio Marchesini.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a clinical/biochemical condition associated with the metabolic syndrome. As the disease stems from excess calorie intake and lack of physical activity, the correction of unhealthy lifestyles is the background of any prevention and treatment strategy; drugs should remain a second-line treatment. Several studies have shown that weight loss and physical activity, the cornerstones of a healthy lifestyle, have a specific therapeutic role in NAFLD, preventing disease progression and reducing the burden of disease. Prescriptive diets have a limited long-term efficacy; after a short period, most patients resume their old habits and weight regain is the rule. Physical activity, usually in combination with diet, but also independent of weight loss, improves liver enzymes and reduces liver fat, with uncertain results on hepatic necroinflammation; however, making patients increase their physical activity is very difficult. Only a behavioral approach may give patients the practical instruments to achieve their eating and exercise goals, incorporate them into lifestyle, and maintain the results for a long period, thereby possibly guaranteeing long-term durability of change. Cognitive-behavior treatment should be provided to patients at risk of advanced liver disease, and this action should be coupled with prevention strategies at the population level. Only a synergistic approach and a global societal response might be effective in reducing the burden of advanced liver disease and premature death due to NAFLD/NASH (non-alcoholic steatohepatitis). Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20460922     DOI: 10.1159/000282101

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  19 in total

Review 1.  Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Melanie D Beaton
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

2.  NAFLD: The role of exercise in treating NAFLD.

Authors:  Elena Reynoso; Joel E Lavine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-22       Impact factor: 46.802

Review 3.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

Review 4.  Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?

Authors:  Bülent Baran; Filiz Akyüz
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

5.  Pharmacologic Management of Nonalcoholic Steatohepatitis.

Authors:  Brent A Neuschwander-Tetri
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-10

6.  A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study.

Authors:  Valentina Volynets; Jürgen Machann; Markus A Küper; Ina B Maier; Astrid Spruss; Alfred Königsrainer; Stephan C Bischoff; Ina Bergheim
Journal:  Eur J Nutr       Date:  2012-04-28       Impact factor: 5.614

7.  Liver enzymes and psychological well-being response to aerobic exercise training in patients with chronic hepatitis C.

Authors:  Shehab M Abd El-Kader; Osama H Al-Jiffri; Fadwa M Al-Shreef
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

8.  Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress.

Authors:  Wan-Jun Zhao; Yang-Ping Bian; Qiu-Hui Wang; Fei Yin; Li Yin; Yong-Lan Zhang; Jian-Hui Liu
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

9.  GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.

Authors:  Shvetank Sharma; Jamie E Mells; Ping P Fu; Neeraj K Saxena; Frank A Anania
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

10.  Garlic-Derived S-Allylmercaptocysteine Ameliorates Nonalcoholic Fatty Liver Disease in a Rat Model through Inhibition of Apoptosis and Enhancing Autophagy.

Authors:  Jia Xiao; Rui Guo; Man-Lung Fung; Emily C Liong; Raymond Chuen Chung Chang; Yick-Pang Ching; George L Tipoe
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.